Company Type

• Top 20 Pharma: 23.4%
• Small/Mid-Tier Pharma: 18.0%
• Generic Pharma: 10.1%
• Virtual Pharma: 9.8%
• Emerging Biopharma: 8.2%
• Specialty Pharma: 7.0%
• Top 10 Biopharma: 6.3%
• Consumer/OTC Healthcare: 3.5%
• Other: 13.6%

Job Function

• R&D: 21.5%
• Corporate Management: 13.0%
• QA/QC/Validation: 12.3%
• Project Manager: 9.5%
• Contract Manager: 6.6%
• Purchasing/Sourcing: 5.7%
• Production/Manufacturing/Packaging: 5.7%
• Business Development: 5.7%
• Marketing/Sales: 5.4%
• Clinical Research: 4.1%
• Supply Chain Manager: 3.5%
• Regulatory Affairs: 2.5%
• Engineering: 1.3%
• Other: 3.2%

Signs of Improvement?

Last year, a whopping 62% of total respondents believed that they’d spend the same or less on outsourcing spending in the coming year; this year, that dipped to 55%. Happily, the “10%+ less spending than previous year” respondents dropped from to 13%, from 23% last year, while no change increased from to 29% of all correspondents, from 25% last year.

Along those lines, 35% of respondents said that they had cancelled outsourcing projects in the previous year due to the economy; the same percentage as in our 2009 survey. We added “to reduce company size” to our responses for “Why does your company outsource?”; 7% of respondents chose that answer, led by Top 20 Pharma, with 41% of those responses.


Editor
Contract Pharma